Abstract: The present invention relates to a new crystalline modification of 6-(4-chlorophenyl)-2,2-dmethyl-7-phenyl-2, S-dihydro-1H-pyrrolizin-S-ylacetic acid which is referred to as polymorph B. It has a peak in the solid state 13C-NMR spectrum (with adamantane as external reference standard; CH group d=29.45 ppm) in the range from 179.8 to 180.2 ppm and can be processed directly to a pharmaceutical formulation.
Type:
Application
Filed:
March 20, 2006
Publication date:
August 20, 2009
Applicant:
Merckle GmgH
Inventors:
Wolfgang Albrecht, Thomas Kammermeier, Hans-Gunter Striegel, Philipp Merckle, Stefan Laufer